Company Encyclopedia
View More
name
SAB Biotherapeutics
SABS.US
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc.
1.945 T
SABS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking253/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.25%D
    • Profit Margin16338.32%A
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-92.42%E
    • Net Profit YoY90.59%A
    • Total Assets YoY241.00%A
    • Net Assets YoY347.32%A
  • Cash ScoreE
    • Cash Flow Margin-2.67%D
    • OCF YoY-92.42%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio10.02%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

    SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a "Moderate Buy" consensus from five research firms. The stock has a 1-year price target of $9.33. Analysts' ratings include one "sell," three "buy," and one "strong buy." Recent institutional investments have been made, and the stock is currently priced at $3.70. The company focuses on developing human polyclonal immunotherapeutic antibodies.

    Market Beat·
    US
    SABS
    +4.74%
    Market Beat·
    US
    SABS
    +4.74%

    SAB Biotherapeutics Reports Positive Q3 2025 Earnings

    SAB Biotherapeutics, Inc. reported a net income of $45.4 million for Q3 2025, a significant improvement from a net loss of $10.3 million in the same period last year. This was driven by a $61.6 million change in the fair value of warrant liabilities. The company ended the quarter with $29.4 million in cash and raised $168.7 million through a private placement. Operating expenses were $12.7 million, with $9 million in R&D. Stockholders’ equity rose to $165 million. The company focuses on advancing SAB-142 for type 1 diabetes and anticipates needing more capital for future development.

    Tip Ranks·
    US
    SABS
    +4.74%
    Tip Ranks·
    US
    SABS
    +4.74%

    SAB Biotherapeutics posts Q3 net income of $45.4 million

    SAB Biotherapeutics Inc. reported a Q3 net income of $45.4 million in 2025, reversing a net loss of $10.3 million in 2024. For the nine months ended September 30, 2025, net income was $30.1 million, up from a net loss of $22.7 million in the prior year. Cash and equivalents totaled $161.5 million as of September 30, 2025. R&D expenses increased to $9.0 million for the quarter. The company initiated a Phase 2b trial for SAB-142 in autoimmune type 1 diabetes.

    Reuters·
    US
    SABS
    +4.74%
    Reuters·
    US
    SABS
    +4.74%

    SAB Biotherapeutics to Present at UBS Global Healthcare Conference

    SAB Biotherapeutics Inc. will present at the UBS Global Healthcare Conference on November 10, 2025, in West Palm Beach, FL. The company is focused on developing human anti-thymocyte immunoglobulin for autoimmune diseases, particularly in delaying type 1 diabetes progression in new onset Stage 3 patients. Management will participate in a fireside chat at 2:45 p.m. ET.

    Reuters·
    US
    SABS
    +4.74%
    Reuters·
    US
    SABS
    +4.74%

    SAB Biotherapeutics (SABS) Receives a Rating Update from a Top Analyst

    Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Disc Medicine, and MoonLake Immunotherapeutics. According to TipRanks, Smith has an average return of 44.1% and a 54.90% success rate on recommended stocks. SAB Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.40.

    Tip Ranks·
    US
    SABS
    +4.74%
    Tip Ranks·
    US
    SABS
    +4.74%
    © 2025 Longbridge｜Disclaimer